Abstract Library

#4501 Efficacy and safety of surufatinib in unresectable or metastatic grade 3 neuroendocrine tumours (NET G3): A national multi-centre, retrospective study

Introduction: Currently, there are limited treatment options for NET G3 and therapeutics for NET G1/2 may be considered as alternatives.

Conference:

Presenting Author: Hao J

Authors: Wang J, Zhang N, Liang Y, Long J, Chi Y,

Keywords: surufatinib, NET G3,

#4397 DNA repair enzyme regulation strategy for enhanced pancreatic neuroendocrine tumour therapy via targeting siRNA-lipid nanoparticles

Introduction: Pancreatic neuroendocrine tumours (panNETs) originate from neuroendocrine cells with high rates of metastasis, rendering many patients’ ineligible for surgical resection. The first-line chemotherapeutic agent temozolomide (TMZ) for metastatic panNETs faces challenges related to resistance, primarily mediated by the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT).

Conference:

Presenting Author: Wang F

Authors: Wang F, Xu J, Xu X, Qin Y, Chen J,

Keywords: Lipid nanoparticle, siRNA, DNA repair enzyme, pancreatic neuroendocrine tumour, temozolomide,

#3276 Increasing compliance of an oral oncolytic through a novel clinical nurse educator model

Introduction: A patient education platform to help navigate medication coordination and symptom management leads to improved adherence and effective patient-HCP communication. Historically, cancer patients have lower rates of oral therapy adherence (~16%) versus patients receiving infusion therapy.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Gaytan P, Weinman L, Early J, Ricardi D, Kifle B,

Keywords: adherence, clinical nurse educator, CNE, NSP, nurse support program, oral oncolytic,

#3165 Clinical characteristics and long-term follow-up of rectal neuroendocrine neoplasms: A single center study

Introduction: Rectal neuroendocrine neoplasms (rNEN) require more evidence on its clinical characteristics, therapeutics and prognosis.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Zhang J, Lu M, Li J,

Keywords: overall survival, rectal neuroendocrine neoplasm, prognostic analysis, therapy,

#3030 Targeting CXCR4 and Thioredoxin Reductase in Theranostics of Atypical Carcinoid and Neuroendocrine Carcinoma

Introduction: Atypical carcinoid and small cell lung cancer (SCLC) are currently incurable. There is thus a critical need for new diagnostic and therapeutic strategies for lung neuroendocrine neoplasms (LNEN). Chemokine receptor 4 (CXCR4), a G protein coupled receptor and theranostic target, plays a crucial role in metastases of LNEN. We hypothesize combination of thioredoxin reductase (TR) inhibitor represents a metabolic strategy to enhance cytotoxicity in peptide-receptor radionuclide therapy (PRRT) of LNEN.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Liu D

Authors: Liu D, Fath M, Robles Planells C, Balk E, Bellizzi A,

Keywords: CXCR4, thioredoxin reductase inhibitor, theranostics, atypical carcinoid, small cell lung cancer,